M
ethicillin-resistant Staphylococcus aureus (MRSA) has been one of the most important pathogens responsible for health care-associated infections since the 1960s (1); the mortality rate due to MRSA bacteremia ranges from 20% to 50% (2, 3) . In addition, the recent emergence and spread of community-associated MRSA (CA-MRSA) in health care settings have increased the importance of this microorganism (4) . CA-MRSA has also emerged as an important pathogen in South Korea (5) , where its genetic profile differs markedly from that in other countries (6) (7) (8) .
The staphylococcal cassette chromosome mec element (SCCmec) harbors the mecA gene, which is responsible for the methicillin resistance of S. aureus (9) . Among 11 types of SCCmec to date (10) (11) (12) , it is well known that newly arising CA-MRSA is commonly associated with SCCmec types IV and V, whereas traditional health care-associated MRSA (HA-MRSA) is commonly associated with SCCmec types I, II, and III (13) . Accordingly, understanding the different clinical outcomes of MRSA bacteremia according to SCCmec type is important when considering the recent epidemiologic changes and increasing importance of CA-MRSA (4) . Although many studies have sought to clarify clinical outcomes according to SCCmec type, the results do not always agree (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , perhaps due to geographical differences in the presence of virulence determinants.
Several virulence factors have been reported to be associated with the clinical outcomes of MRSA bacteremia. The accessory gene regulator (agr) is a global regulator gene controlling the expression of major virulence factors, such as Panton-Valentine leukocidin (PVL), ␣-hemolysin, and phenol-soluble modulin (PSM) (24) , and its dysfunction is known to be correlated with higher mortality and prolonged bacteremia, but its precise mechanism has yet to be established (25, 26) . PSM-mec is encoded in SCCmec elements, mainly in types II and III (27) , and is known to be responsible for the reduced virulence of MRSA due to the repression of PSMs in the core genome (28) . PVL is a leukocidin, an established virulence determinant of CA-MRSA, although its importance has recently been questioned (29) .
We aimed to compare MRSA bacteremia-attributed mortality in SCCmec types II/III and type IV, as well as to identify the microbiological factors associated with MRSA bacteremia-attributed mortality related to SCCmec type.
MATERIALS AND METHODS
Study design and patients. Data from all episodes of MRSA bacteremia between January 2009 and May 2013 were prospectively collected at Seoul National University Bundang Hospital (a 900-bed tertiary-care hospital in Seongnam, South Korea). All adult patients (Ն15 years of age) suffering their first MRSA bacteremia episodes were enrolled. Excluded from this study were cases of polymicrobial infection or suspected contamination, as well as those for which bloodstream isolates were unavailable or the outcomes could not be evaluated due to early discharge or transfer without follow-up.
Data collection and definitions. Data for patient sex, age, onset of bacteremia, first positive blood culture in the intensive care unit (ICU), nosocomial or community acquisition of the bacteremia with a history of previous health care contact (30) , primary site of infection, and antibiotic treatment were collected prospectively (31, 32) . The following data were retrospectively reviewed for this study: Charlson's comorbidity weighted index (33) , the McCabe and Jackson classification of underlying illness (classified as rapidly fatal when death was expected within days or weeks, ultimately fatal when death was expected within months or years, and nonfatal when death was not expected), steroid use (equivalent to 20 mg of prednisolone per day Ն1 week) or chemotherapy within 30 days, presence of neutropenia (absolute neutrophil count, Ͻ500/l), severity of illness as measured by the Pitt bacteremia score (34) and sequential organ failure assessment (SOFA) score (35) , presentation with septic shock, eradication of the infection foci, and in-hospital death.
Antimicrobial therapy was considered inappropriate if the isolate was not susceptible to the chosen antibiotic in vitro. Empirical and definitive antibiotics were defined as antibiotics administered within the first 48 h and those used after a report of antibiotic susceptibility of the isolates, respectively. Eradicable foci were defined as the infections involving foreign bodies or solely drainable abscesses. Among them, eradicated foci included the cases in which indwelling foreign bodies or abscesses had been removed or drained (36) .
MRSA bacteremia-attributed mortality was predefined as a positive blood culture for MRSA at the time of death or a persistent focus of MRSA infection associated with clinical signs of sepsis; this definition is somewhat modified from those used in previous studies (37, 38) .
The study was approved by the institutional review board of Seoul National University Bundang Hospital.
Microbiological analyses.
BacT/Alert FA and FN bottles (bioMérieux, Durham, NC) were used for all blood cultures. In accordance with Clinical and Laboratory Standards Institute guidelines (39), antimicrobial susceptibility was identified with a Vitek 2 (bioMérieux, Marcy L'Etoile, France), and the MICs for vancomycin were determined by Etest (bioMérieux, Lyon, France) and the broth microdilution method.
The following microbiological tests were additionally performed for all the blood MRSA isolates: multiplex PCRs for SCCmec type (40) , typing of Staphylococcus protein A (spa) polymorphisms (41) , typing of the agr locus (42) , and PCR for the lukS-PV and lukF-PV genes for PVL (43) were performed as described. The function of the agr locus was investigated by ␦-hemolysin expression assays using S. aureus strain RN4220, and the absence of, or barely detectable, synergistic hemolysis was defined as agr dysfunction (44) . The psm-mec gene and its mutations were examined by amplification and sequencing, as previously described (28) .
Pharmacokinetic-pharmacodynamic parameters. Individual 24-h area under the concentration-time curve (AUC 24 ) values were calculated using the Pharmacokinetic system (PKS) version 1.10 (Abbott Laboratories), which uses a two-compartment volume clearance model with the maximum a posteriori probability Bayesian approach, as previously reported (32, 45) . The patients who met the following criteria were excluded from the AUC 24 analysis: (i) died within 72 h after index culture, (ii) received renal replacement therapy, (iii) received vancomycin for Ͻ72 h, (iv) did not receive vancomycin within 5 days of index culture, and (v) were not checked for vancomycin serum concentration within the first 5 days of treatment.
Statistical analyses. Cases involving SCCmec types II and III were grouped together and compared with cases involving type IV after taking account of their epidemiologic background. To prevent bias due to nonattributed mortality resulting from MRSA bacteremia, multinomial logistic regression was used. Variables with a P value of Ͻ0.05 in the univariable analyses were subjected to multivariable analysis in a backward stepwise manner. Of the many parameters representing acute severity of illness, only the Pitt bacteremia score was included in the multivariable analysis to avoid multicolinearity. For all analyses, a P value of Ͻ0.05 was considered significant for two-tailed tests. PASW for Windows (version 18 software package; SPSS, Inc., Chicago, IL, USA) was used throughout.
RESULTS
Patients and SCCmec types. Of a total of 252 nonduplicate MRSA bacteremias during the study period, 195 were included in this study after excluding 13 cases with polymicrobial infections, 12 with suggested contamination, 21 with unavailable bloodstream isolates, and 11 with clinical outcomes that could not be evaluated (Fig. 1 ). There were 137 (70.3%) cases of SCCmec types II/III and 58 (29.7%) cases of type IV.
Frequent diagnoses of patients with SCCmec types II/III nosocomial MRSA infection (n ϭ 100) at admission were solid tumor (n ϭ 31), infectious disease not due to MRSA (n ϭ 19), cardiovascular disease (n ϭ 16), gastrointestinal tract disease (n ϭ 6), and hematologic malignancy (n ϭ 5). Of the 34 patients who were in the ICU when the MRSA bacteremia occurred, 31 involved SCCmec types II/III, and only three involved SCCmec type IV. The most frequent reason for ICU admission in patients with SCCmec types II/III was postoperative care (n ϭ 14), followed by respiratory failure due to pneumonia or pulmonary edema (n ϭ 13). Vancomycin was chosen in all the cases for which an appropriate definitive antibiotic was used, with only one exception, namely, linezolid.
MRSA bacteremia-attributed mortality according to SCCmec type. The number of deaths attributed to MRSA bacteremia, deaths not attributed to MRSA bacteremia, and survivors were 44 (22.6%), 24 (12.3%), and 127 (65.1%), respectively. Among those MRSA bacteremia-attributed deaths, a positive blood culture for MRSA at the time of death was demonstrated in 24 (54.5%) cases, Tables  2 and 3) . No difference was noted when the SOFA score or presentation with septic shock was included in the multivariable analysis instead of the Pitt bacteremia score. Also, when a separate focus of infection was used in multivariable analysis rather than only an eradicable focus in an attempt to control for the effect of differences in the rates of infection at different primary sites, SCCmec type IV was still independently correlated with a lower risk of mortality than were types II/III (aOR, 0.19; 95% CI, 0.06 to 0.59; P ϭ 0.004, data not shown). and no mutations were detected in those cases. Of all the isolates, only two were positive for the PVL genes, and both were SCCmec type IV spa type t008. Pharmacokinetic-pharmacodynamic parameters. Of the total 195 patients, 86 (44.1%) were excluded from the AUC 24 analysis by the criteria already described. Moreover, 26 (59.1%) of 44 cases of MRSA bacteremia-attributed mortality were excluded.
Microbiological characteristics according to
The AUC 24 /MIC values did not differ significantly according to SCCmec type or clinical outcome when assessed using the two MIC methods (Tables 4 and 5) .
Microbiological factor associated with MRSA bacteremia-attributed mortality. Dysfunctional agr was more prevalent in the patients with MRSA bacteremia who died than in those who survived (P ϭ 0.018, Table 5 ). Multivariable analysis showed that agr dysfunction was independently related to MRSA bacteremia-attributed mortality (aOR, 4.71; 95% CI, 1.72 to 12.92; P ϭ 0.003, Table 6 ).
DISCUSSION
This is the first study of MRSA bacteremia-attributed mortality according to SCCmec type in the context of the presence or absence of various virulence determinants. MRSA with SCCmec type IV was independently associated with a lower risk of MRSA bacteremia-attributed mortality than was MRSA with SCCmec types II/III. There were significant differences in agr dysfunction and PSM-mec between these groups but not in PVL. After adjusting for clinical factors, MRSA bacteremia-attributed mortality was significantly associated with agr dysfunction but not with PSM-mec.
There have been many studies of the effect of SCCmec type on the clinical outcomes of MRSA bacteremia. Most of the comparisons were between types II and IV, and some studies reported that there were no significant differences between these two groups (14-18), while others reported that type IV was associated with a worse prognosis (19, 20) . In contrast, data from Taiwan suggested that SCCmec type II was associated with a poorer outcome than was type IV (21) (22) (23) . Since it was difficult to understand such opposing results simply in terms of clinical factors, we compared MRSA bacteremia-attributed mortality between SCCmec types II/ III and type IV as a function of the virulence determinants harbored by the infecting bacteria. After a careful consideration of clinical factors, such as underlying disease, severity of acute illness, mode of infection acquisition, primary site of infection, and usage of antimicrobial agents, we concluded that microbiological as opposed to clinical characteristics may well play an important role in SCCmec type-dependent clinical outcomes.
Dysfunctional agr was another independent risk factor for MRSA bacteremia-attributed mortality in this study. Since there were significant differences in the frequency of agr dysfunction depending on SCCmec type, it seems very likely that the poorer outcome of SCCmec types II/III is related to their higher frequency of agr dysfunction. In previous reports, the rates of agr dysfunction in SCCmec types II and IV were 17 to 43% and 3 to 11%, respectively, and no significant differences in clinical outcome were found between those types (46, 47) . The rate of agr dysfunction in SCCmec type IV in the present analysis was in the range of those already reported; however, it was much higher in SCCmec types II/III, again suggesting a close connection between their poorer prognosis and their higher rate of agr dysfunction.
Only 21.4% of our SCCmec types II/III strains possessed psmmec, in contrast to another study in which Ͼ90% of the SCCmec type II strains harbored psm-mec (28) . It is possible that this low frequency of psm-mec-positive strains is related to their higher rate of MRSA bacteremia-attributed mortality in this study.
The rate of positivity for the PVL genes among the CA-MRSA strains varied from about 10% to Ͼ70% (14-19, 21, 22) . Interestingly, it was Ͻ30% in most studies from Taiwan (15-17, 21, 22) , where SCCmec type II rather than type IV was related to poorer outcomes, while it was Ͼ70% in most studies from the United States (14, 18, 19) , where infections with SCCmec type IV had poorer outcomes. The low frequency of genes for PVL (3.4%) may have contributed to the better prognosis of SCCmec type IV MRSA bacteremia in the present study.
Two meta-analyses of the effect of vancomycin MIC on treatment outcomes reached conflicting conclusions (48, 49) . In the present work, we noted no significant relationship between vancomycin MIC and MRSA bacteremia-attributed mortality, and this is consistent with the hypothesis that vancomycin MIC is a surrogate marker for pathogen-specific virulence (48) . Another possible explanation is that vancomycin MIC alone may be a worse predictor of poor prognosis than is AUC 24 /MIC (32) . Although we did not find any statistically significant effect of the vancomycin AUC 24 /MIC according to SCCmec type or clinical outcome in this study, further studies are warranted, because some degree of selection bias may have occurred as a consequence of excluding numerous cases.
This was a retrospective cohort study with a limited sample size. We could not rule out the possibility that selection bias occurred when cases were excluded because of the unavailability of bloodstream isolates or of early discharge or transfer of patients. In addition, the PCR-based evaluation of virulence determinants should be interpreted with some caution, because it might not directly reflect in vivo expression. Although there were some ambiguities when assigning the cause of death by retrospective chart review, we believe that we could substantially reduce the impact of nonattributed mortality, such as deaths by malignancy, liver cirrhosis, or suicide, by introducing MRSA bacteremia-attributed mortality. It is also worth noting that because all the isolates in this study belonged to SCCmec types II, III, and IV, we did not perform additional screening for novel SCCmec types.
Although our study has clear limitations, the data seem sufficiently reliable to allow us to conclude that SCCmec type IV is associated with lower MRSA bacteremia-attributed mortality than are SCCmec types II/III in South Korea, and this may be explained by the high rate of agr dysfunction in SCCmec types II/III. 
